Oklo stock tumbles as Financial Times scrutinizes valuation
Director Myrtle S. Potter of Guardant Health, Inc. (NASDAQ:GH) sold 26 shares of common stock on October 17, 2025, at a price of $66.95, for a total value of $1740. Following the transaction, Potter directly owns 18324 shares of Guardant Health . The stock, currently trading at $70.22, has shown remarkable strength with a 206% return over the past year and is trading near its 52-week high. According to InvestingPro analysis, the company appears overvalued at current levels, with investors eagerly awaiting the upcoming earnings report on October 29. InvestingPro subscribers have access to 8 additional key insights about Guardant Health, along with comprehensive valuation metrics and expert analysis in the Pro Research Report.
In other recent news, Guardant Health has received approval from the U.S. Food and Drug Administration for its Guardant360 CDx blood test as a companion diagnostic for Eli Lilly’s breast cancer drug, Inluriyo. This approval will enable the test to identify patients with specific ESR1 mutations who may benefit from the treatment. Following the company’s 2025 Investor Day, Bernstein SocGen Group reiterated its Outperform rating on Guardant Health with a price target of $60. JPMorgan also maintained its Overweight rating after the company updated its 2028 financial targets, now projecting approximately $2.2 billion in revenue. Guggenheim raised its price target for Guardant Health to $67, highlighting the company’s recent product launches. Similarly, TD Cowen increased its price target to $72, noting the "upbeat" presentation during the Investor Day event. These developments reflect ongoing interest and positive sentiment from analysts regarding Guardant Health’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.